News Story: Full Text
Sponsored By
Gleolan for brain tumors
Please Click On The Above Banner For More Details
Braintumor Website


Dr. S. R. Burzynski Gives Presentation at ICACT in Paris


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://www.primezone.com/newsroom/?d=72757

Posted on: 02/15/2005

Source: Burzynski Research Institute

Dr. S. R. Burzynski Gives Presentation at ICACT in Paris

PARIS, Feb. 15, 2005 (PRIMEZONE) -- Stanislaw R. Burzynski, M.D., Ph.D., founder and CEO of the Burzynski Clinic and President of the Burzynski Research Institute, Inc. (OTCBB:BZYR) in Houston, gave a presentation entitled "Targeted Therapy with Antineoplastons A10 and AS2-1 (ANP) of High Grade, Recurrent and Progressive Brain Stem Glioma (HBSG)" to the 16th International Congress on Anti-Cancer Treatment (ICACT) -- February 1-4, 2005.

The objective of Dr. Burzynski's presentation was to describe an evaluation of the outcome for patients diagnosed with HBSG, including glioblastoma multiforme and treated with ANP in four Phase II clinical trials -- testing the hypothesis that ANP treatment yields longer survival and a greater number of objective responses than current standard therapy.

A10 and AS2-1 (ANP), which Dr. Burzynski and his team developed in the 1990's, are synthetic derivatives of glutamine, isoglutamine and phenylacetic acid. These agents have been found to work as molecular switches that may turn on tumor suppressor genes and turn off oncogenes.

Dr. Burzynski believes that research results in patients receiving ANP therapy lead to the following conclusions:

-- Greater than a 5-year survival rate in a small group of HBSG patients.

-- Longer progression free survival responses than patients undergoing standard therapy.

-- Longer overall survival than patients undergoing standard therapy.

-- Higher positive response rate than those receiving standard therapy.

-- ANP is well tolerated -- with rare, sporadic and reversible adverse drug reactions.

Prior to this presentation, Dr. Burzynski was a featured speaker at the Cleveland Clinic's Annual Brain Tumor Symposium, Neuro-Oncology 2005, held in Orlando, Florida, January 29-31, 2005.

Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. BRI cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to BRI's ability to obtain regulatory approval for Antineoplastons A10 and AS2-1. BRI does not undertake to update any such forward-looking statements or to publicly announce developments or events relating to the matters described herein.

The Burzynski Research Institute logo can be found at: http://www.primezone.com/newsroom/prs/?pkgid=1291

CONTACT:

The Burzynski Research Institute
D. R. Anderson
(713) 335-5697
info@burzynskiresearch.com
www.burzynskiresearch.com



Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740